Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.
While the drugs in this field are very potent, chemotherapy resistance presents itself as a major challenge when treating patients with ovarian cancer. Burgess says that researchers believed targeted therapies would help overcome such barriers, but chemotherapy resistance becomes an issue primarily in long-term treatment.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More